Published in Vaccine Weekly, June 18th, 2003
Generex will collaborate with privately owned Antigen Express, which will use its proprietary Ii protein suppression and Ii-Key peptide vaccine-enhancing technologies in the development of SARS vaccines. Antigen develops a range of therapeutics for the treatment of cancer, autoimmune, infectious, and allergic diseases. The agreement is subject to the completion of due diligence and formal documentation.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly